Zacks Research Comments on Apellis Pharmaceuticals, Inc.’s Q1 2025 Earnings (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLSFree Report) – Stock analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a report released on Tuesday, April 23rd. Zacks Research analyst R. Department now anticipates that the company will post earnings of ($0.01) per share for the quarter, down from their previous estimate of $0.06. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.33) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q3 2025 earnings at $0.39 EPS and FY2025 earnings at $1.05 EPS.

Apellis Pharmaceuticals (NASDAQ:APLSGet Free Report) last released its earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, meeting the consensus estimate of ($0.73). The firm had revenue of $146.38 million for the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The company’s revenue for the quarter was up 545.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.50) EPS.

A number of other equities analysts have also recently issued reports on the company. Mizuho restated a “neutral” rating and set a $60.00 price objective on shares of Apellis Pharmaceuticals in a report on Wednesday, March 27th. Needham & Company LLC restated a “buy” rating and set a $85.00 price objective on shares of Apellis Pharmaceuticals in a report on Tuesday, April 9th. Robert W. Baird restated an “outperform” rating and set a $81.00 price objective on shares of Apellis Pharmaceuticals in a report on Tuesday, February 6th. Oppenheimer boosted their price objective on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an “outperform” rating in a report on Tuesday, January 30th. Finally, UBS Group boosted their price objective on Apellis Pharmaceuticals from $87.00 to $89.00 and gave the company a “buy” rating in a report on Monday, March 4th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $77.93.

View Our Latest Stock Analysis on APLS

Apellis Pharmaceuticals Stock Performance

NASDAQ APLS opened at $49.93 on Thursday. The business’s 50 day moving average price is $58.61 and its 200-day moving average price is $57.37. Apellis Pharmaceuticals has a fifty-two week low of $19.83 and a fifty-two week high of $94.75. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10. The company has a market cap of $6.02 billion, a P/E ratio of -11.15 and a beta of 0.88.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in APLS. Jennison Associates LLC raised its position in shares of Apellis Pharmaceuticals by 79.8% in the 3rd quarter. Jennison Associates LLC now owns 3,542,209 shares of the company’s stock worth $134,746,000 after acquiring an additional 1,571,606 shares in the last quarter. Assenagon Asset Management S.A. increased its position in Apellis Pharmaceuticals by 109.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock valued at $128,400,000 after buying an additional 1,121,497 shares in the last quarter. Norges Bank acquired a new position in Apellis Pharmaceuticals during the 4th quarter valued at about $56,640,000. Price T Rowe Associates Inc. MD increased its position in Apellis Pharmaceuticals by 38.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock valued at $147,277,000 after buying an additional 677,098 shares in the last quarter. Finally, Polar Capital Holdings Plc increased its position in Apellis Pharmaceuticals by 126.6% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company’s stock valued at $40,089,000 after buying an additional 588,875 shares in the last quarter. 96.29% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 906 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $64.14, for a total value of $58,110.84. Following the completion of the sale, the general counsel now directly owns 104,171 shares in the company, valued at approximately $6,681,527.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, General Counsel David O. Watson sold 906 shares of the business’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $64.14, for a total value of $58,110.84. Following the completion of the transaction, the general counsel now directly owns 104,171 shares of the company’s stock, valued at approximately $6,681,527.94. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, General Counsel David O. Watson sold 781 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $67.77, for a total value of $52,928.37. Following the completion of the transaction, the general counsel now directly owns 103,390 shares of the company’s stock, valued at $7,006,740.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 381,011 shares of company stock worth $23,463,657. 7.50% of the stock is currently owned by company insiders.

Apellis Pharmaceuticals Company Profile

(Get Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

See Also

Earnings History and Estimates for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.